NervGen PharmaNGEN -1.06%22 Quick Ratio is 0.00 as of Mar. 2026. GuruFocus rates NGEN with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 1,416 Biotechnology companies, NervGen Pharma ranks worse than 77.97% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. NervGen Pharma's quick ratio for the quarter that ended in Mar. 2026 was 0.00.
NervGen Pharma has a quick ratio of 0.00. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for NervGen Pharma's Quick Ratio or its related term are showing as below:
NGEN'
s Quick Ratio Range Over the Past 10 Years
Min: 0.79 Med: 4.25 Max: 30.14
Current: 1.16
During the past 9 years, NervGen Pharma's highest Quick Ratio was 30.14. The lowest was 0.79. And the median was 4.25.
NGEN's Quick Ratio is ranked worse than 77.97% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs NGEN: 1.16
NervGen Pharma (NAS:NGEN) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
NervGen Pharma Quick Ratio Related Terms
NervGen Pharma Quick Ratio Historical Data
* Premium members only.
The historical data trend for NervGen Pharma's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, NervGen Pharma's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NervGen Pharma Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NervGen Pharma's Quick Ratio distribution charts can be found below:
* The bar in red indicates where NervGen Pharma's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
NervGen Pharma's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NervGen Pharma (NGEN) has a Quick Ratio of 0.00 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on NervGen Pharma and its competitors. Over the past decade, NervGen Pharma's Quick Ratio has ranged from 0.79 to 30.14. According to the industry distribution chart, NervGen Pharma ranks #1104 out of 1416 companies in the Biotechnology industry, placing it in the top 78%.
Is NervGen Pharma's Quick Ratio too high?
NervGen Pharma's current Quick Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 0.79 to a high of 30.14. Based on the distribution chart, NervGen Pharma ranks #1104 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NervGen Pharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does NervGen Pharma's Quick Ratio compare to CNTN and ELTX?
According to the Biotechnology industry distribution chart, NervGen Pharma ranks #1104 out of 1416 companies for Quick Ratio. This places NervGen Pharma in the lower half of its industry. The industry median Quick Ratio is 3.60. Historically, NervGen Pharma's own Quick Ratio has ranged from 0.79 to 30.14 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on NervGen Pharma and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NervGen Pharma's current Quick Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NervGen Pharma stock overvalued right now?
NervGen Pharma (NGEN) has a current Quick Ratio of 0.00. The current Quick Ratio is 0.00. NervGen Pharma's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For NervGen Pharma (NGEN), the current Quick Ratio is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
22GF Score
Get the complete analysis for NGEN
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGEN has been successfully added to your 
